^
    Back
    Association details:
    Biomarker:MET amplification
    Cancer:Non Small Cell Lung Cancer
    Drug:Haiyitan (gumarontinib) (c-MET inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Study to Evaluate the Safety and Anti-tumor Activity of SCC244

    Excerpt:
    ...In Phase Ia, histologically confirmed NSCLC (including sarcomatoid carcinoma) with c-Met alterations defined as c-Met gene amplification ≥ 5 copies or c-Met protein overexpression (IHC 3+) or c-Met exon 14 skipping mutation....
    Trial ID:
    NCT03466268
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2020
    Title:

    A phase I clinical trial to assess the safety, pharmacokinetics, and antitumor activity of glumetinib (SCC244) in patients with advanced non-small cell lung cancers (NSCLCs).

    Published date:
    05/28/2020
    Excerpt:
    Glumetinib was well tolerated at doses up to 400 mg once daily and demonstrated clinical activity in advanced NSCLC with MET alterations….4 patients (3 with MET amplification) had a best of response of stable disease.
    DOI:
    10.1200/JCO.2020.38.15_suppl.e21702
    Trial ID:
    NCT03466268